ArticleJournal for immunotherapy of cancer2023

Correction: CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.

No numbers read from the abstract.

Not cited yet